Trial Profile
Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Study of PM00104 Administered Intravenously Over 1 Hour Daily for 5 Days, Every 3 Weeks, to Subjects With Advanced Malignant Solid Tumors or Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs PM 00104 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 15 Oct 2008 Status changed from recruiting to discontinued, as reported by Clinicaltrials.gov.
- 07 Nov 2006 New trial record.